Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-12-15
2000-04-11
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514300, 544333, 546122, 546123, C07D47104, C07D40106, C07D40112, A61K 3144, A61K 31435
Patent
active
060488611
ABSTRACT:
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
REFERENCES:
patent: 3843798 (1974-10-01), Cook et al.
patent: 5025025 (1991-06-01), Bhagwat et al.
patent: 5352667 (1994-10-01), Lider et al.
patent: 5455243 (1995-10-01), Duggan et al.
patent: 5668159 (1997-09-01), Jin et al.
Askew Ben C.
Coleman Paul J.
Duggan Mark E.
Halczenko Wasyl
Hartman George D.
Durette Philippe L.
Merck & Co. , Inc.
Rao Deepak R.
Sabatelli Anthony
Shah Mukund J.
LandOfFree
Integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1176826